Magnesium silicide nanoparticles as a deoxygenation agent for cancer starvation therapy (Nature nanotechnology, 2017, 280)Magnesium silicide nanoparticles as a deoxygenation agent for cancer starvation therapy (Nature nanotechnology, 2017, 280) cancer組,Coordinator: 黃柏憲

報告日期: 2017/03/07
報告時間: 3:10/4:00
報告學生: 張詠傑
講評老師: 謝達斌
附件下載: 下載[1615-1487727577-1.pdf] 

Magnesium silicide nanoparticles as a deoxygenation agent for cancer starvation therapy 

Chen Zhang, Dalong Ni, Yanyan Liu, Heliang Yao, Wenbo Buand Jianlin Shi

Nature nanotechnology. January 9 2017

Speaker: Yung-Chieh, Chang                                                         Date: 2017.03.07

Commentator: Dr. Dar-Bin Shieh                                                     Plate: Room 602

Abstract:

Advanced nanotechnology has been suggested as a novel strategy for cancer treatment and has been making significant improvements in cancer therapy in the past decade. In clinical studies, several functional nanoparticles, including nanoshlles, liposomes, polymeric carriers and polymer-conjugate drug/protein, had been developed for the treatment of various types of cancer; however, there is few nanoparticles that were designed for tumor starvation therapy. The aim of this study was to develop a novel nanoparticle that can act as a deoxygenation agent (DOA) for cancer therapy. The sizeable (<100 nm) magnesium silicide (Mg2Si) nanoparticles (MS NPs) were first prepared by a self-propagating high-temperature synthesis strategy and subsequently modified with polyvinyl pyrrolidone (PVP) by the authors. At the functional level, MS NPs were shown to be capable of inhibiting cancer cell proliferation and tumor growth in vitro and in vivo. The anti-cancer mechanism was evidenced by that the Mg2Si released silane (SiH4), which efficiently reacted with both tissue-dissolved and haemoglobin-bound oxygen to form silicon dioxide (SiO2) aggregates in the acidic tumor microenvironment. The SiO2 aggregates prevented tumor capillaries from being reoxygenated leading to long-term oxygen scavenging. In conclusion, PVP-modified MS NP could act as DOA for the anti-angiogenic therapy with low side effects.

Reference:

  1. Dan Peer, Jeffrey M. Karp, Seungpyo Hong, Omid C. Farokhzad, Rimona Margalit and Robert Langer. (2007). Nanocarriers as an emerging platform for cancer therapy. Nature nanotechnology. 2, 751-760.
  2. Jianwen Liang, Xiaona Li, Zhiguo Hou, Cong Guo, Yongchun Zhu and Yitai Qian. (2015). Nanoporous silicon prepared through air-oxidation demagnesiation of Mg2Si and properties of its lithium ion batteries. Chemical Communication. 51, 7230-7233.